ArticleStem cells translational medicine2018
Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study.
Article in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02397018 (Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke), which is not on this map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Preclinical studies of conditioned medium of hypoxic-preconditioned mesenchymal stem cell/hypMSC-CM for ischemic stroke: A systematic review.Open veterinary journal · 2026Pooled it
- A review and meta-analysis of stem cell therapies in stroke patients: effectiveness and safety evaluation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Stem cell-based therapies for ischemic stroke: a systematic review and meta-analysis of clinical trials.Stem cell research & therapy · 2020Pooled it
- Stem cell transplantation for ischemic stroke.The Cochrane database of systematic reviews · 2019Pooled it
- Safety and efficacy of allogeneic umbilical cord blood cells and erythropoietin combination therapy in patients with subacute stroke.Stem cell research & therapy · 2025Trial
- A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke.Stem cells translational medicine · 2024Trial
- Cell Therapy for Ischemic Stroke with Nanoparticle-Labeled 293T Cells and Bone Marrow-Derived Mesenchymal Stem Cells: A Feasibility Study.Pharmaceutics · 2026Article
- Molecular Pathophysiology of Ischemic Stroke and Mesenchymal Stem Cell Based Therapeutic Strategies for Neural Tissue Regeneration: A Pre-clinical and Clinical Perspective.Stem cell reviews and reports · 2026Review
- Cell therapy for stroke and spinal cord injury in clinical trials.Stem cells translational medicine · 2026Review
- Mesenchymal stem cells in neurological disorders: Insights from clinical trials.Regenerative therapy · 2025Review
- Review
- Clinical trials and advanced MRI techniques with stem cell therapy for ischemic stroke: present and future perspectives.Journal of translational medicine · 2025Review
- Remodeling and repair of the damaged brain: the potential and challenges of organoids for ischaemic stroke.Journal of translational medicine · 2025Review
- The revolutionary role of placental derivatives in biomedical research.Bioactive materials · 2025Review
- Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Integrin β2 Plays a Significant Role in Therapeutic Angiogenesis Through Hematopoietic Stem Cell Transplantation.Life (Basel, Switzerland) · 2025Article
- Umbilical Cord Blood and UC-MSCs Combined with Low-Dose Immunosuppressant in the Treatment of Elderly Patients with Pure Red Cell Aplastic: A Case Series.Current stem cell research & therapy · 2025Article
- Blood-brain barrier repair: potential and challenges of stem cells and exosomes in stroke treatment.Frontiers in cellular neuroscience · 2025Review
- Brain repair mechanisms after cell therapy for stroke.Brain : a journal of neurology · 2024Review
- Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic.Translational stroke research · 2024Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a major cause of death and long-term disability, affecting one in six people worldwide. The only currently available approved pharmacological treatment for ischemic stroke is tissue plasminogen activator; however, relatively few patients are eligible for this therapy. We hypothesized that intravenous (IV) infusion of banked unrelated allogeneic umbilical cord blood (UCB) would improve functional outcomes in patients with ischemic stroke. To investigate this, we conducted a phase I open-label trial to assess the safety and feasibility of a single IV infusion of non-human leukocyte antigen (HLA) matched, ABO matched, unrelated allogeneic UCB into adult stroke patients. Ten participants with acute middle cerebral artery ischemic stroke were enrolled. UCB units were matched for blood group antigens and race but not HLA, and infused 3-9 days post-stroke. The adverse event (AE) profile over a 12 month postinfusion period indicated that the treatment was well-tolerated in these stroke patients, with no serious AEs directly related to the study product. Study participants were also assessed using neurological and functional evaluations, including the modified Rankin Score (mRS) and National Institute of Health Stroke Scale (NIHSS). At 3 months post-treatment, all participants had improved by at least one grade in mRS (mean 2.8 ± 0.9) and by at least 4 points in NIHSS (mean 5.9 ± 1.4), relative to baseline. Together, these data suggest that a single i.v. dose of allogeneic non-HLA matched human UCB cells is safe in adults with ischemic stroke, and support the conduct of a randomized, placebo-controlled phase 2 study. Stem Cells Translational Medicine 2018;7:521-529.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.